123 results
Page 4 of 7
8-K
EX-99.1
i587cc
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.1
v2tqwdxt
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
EX-99.2
vnxzj
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
424B3
ry143
14 Jul 20
Prospectus supplement
4:05pm
8-K
EX-99.1
4zdffk
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.2
4ine5zz
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.1
jb1zxrdp6ioyybjf1
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.2
mehofx u9e
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
2zwdnysvfcia7eb5e
13 Jan 20
Other Events
8:06am
8-K
04mn296lzivnl2 y9th
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
v4guk cye96
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
7gk7envx2e69rc0
2 Dec 19
Other Events
5:18pm
424B5
eqqkvudjzvugq7mbjkd
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
h8r4xj
26 Nov 19
Prospectus supplement for primary offering
5:18pm